From Allafrica · · 1m 40s
Nigerian Drugmaker Fidson Selected for Global Influenza Antiviral
Nigerian firm Fidson Healthcare Plc joins global effort to produce generic influenza antiviral under Roche-MPP license.
In brief
Nigerian firm Fidson Healthcare Plc joins global effort to produce generic influenza antiviral under Roche-MPP license. Fidson Healthcare Plc, a Nigerian pharmaceutical company, will manufacture generic baloxavir marboxil for 129 countries under a global license agreement with Roche and the Medicines Patent Pool…
Fidson Selected for Global Influenza Antiviral
A Nigerian pharmaceutical company, Fidson Healthcare Plc, has been selected to develop and manufacture a generic version of baloxavir marboxil, an antiviral medicine used to treat influenza.
11 Manufacturers Across 9 Countries
The selected manufacturers are from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam.
Global Licensing Agreement
The selection makes Fidson one of 11 manufacturers across nine countries chosen under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Swiss pharmaceutical company Roche.
MPP's Purpose
The MPP said the arrangement is intended to 'diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.'
“The MPP said the arrangement is intended to 'diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.'”
Fidson's Role in Global Supply
The selection makes Fidson one of the manufacturers that would develop, manufacture and supply generic versions of baloxavir in 129 countries covered by the licence, subject to regulatory authorisation.
Technical Support for Manufacturers
The agreement also gives selected manufacturers access to technical data, reference products for bioequivalence studies and other support to facilitate product development and regulatory approval.
Fidson CEO's Statement
Fidson's Managing Director and Chief Executive Officer, Biola Adebayo, described the selection as a validation of the company's commitment to quality-assured pharmaceutical manufacturing and innovation.
“Being selected by the Medicines Patent Pool as a sublicensee under the Roche-MPP voluntary licensing programme for baloxavir marboxil is both an honour and a validation of Fidson's longstanding commitment to quality-assured pharmaceutical manufacturing, innovation, and improving healthcare outcomes.”
Global Health Security Focus
He said the partnership would allow the company to contribute to efforts to strengthen regional health security and preparedness for future health emergencies.
In short
Fidson Healthcare Plc, a Nigerian pharmaceutical company, will manufacture generic baloxavir marboxil for 129 countries under a global license agreement with Roche and the Medicines Patent Pool.
